Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 3, 2021

View Archived Issues

ADAM9 is a driver of disease severity in COVID-19 and a potential therapeutic target

LncRNA LINC00978 is a potential diagnostic marker of colorectal cancer

SAR-439883 rescues memory deficits and prevents neurodegeneration in animal models of AD

Targeting IRE1-mediated ER stress response and lipid reshuffling for reprogramming TME

PF-00835231 and its prodrug PF-07304814 show promising SARS-CoV-2 antiviral activity

Sanofi patents new YAP1/TEAD interaction inhibitors

Foghorn Therapeutics discloses new PROTACs

UCB identifies new IL-17 modulators

GB005 synthesizes BTK inhibitors

U.S. researchers patent new meayamycin derivatives

Mechanism of KRAS-G12C inhibitors unveiled: RGS3 enhances the GTPase activity of mutant and WT KRAS

KDM5B suppresses antitumor immunity by epigenetic silencing of retroelements in melanoma models

Detachable glucosylated PEG chains allow anti-PD-L1 antibody access to glioblastoma tumors

Low glycemic diets alter lipid availability and influence cancer cell metabolism to affect growth

FTD3-associated reactive astrocytes display autophagy impairments and cause neuronal toxicity

Angelman syndrome gene therapy restores dual-isoform expression of UBE3A in the developing brain

Structure-based optimization identifies potent galactokinase inhibitors

New treatment targets identified in opiate abstinence

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...